IGF-1 DES Peptide

IGF-1 DES (Des(1-3) IGF-1) is a truncated form of IGF-1 missing the first 3 amino acids. This modification eliminates binding to IGFBPs (IGF Binding Proteins), resulting in a compound approximately 10x more potent than full-length IGF-1 because 100% of the peptide remains bioavailable for receptor activation.

IGF-1 DES (also known as Des(1-3)IGF-1) is a truncated analog of human insulin-like growth factor 1 in which the first three N-terminal amino acids (Gly-Pro-Glu) have been removed. This deletion gives rise to a 67-amino acid single-chain polypeptide that retains the three disulfide bonds and overall tertiary fold of the parent IGF-1 molecule, but exhibits markedly altered binding behavior. The biological activity of IGF-1 DES is mediated primarily through the type 1 insulin-like growth factor receptor (IGF-1R), with secondary cross-reactivity at the insulin receptor (IR) and hybrid IGF-1R/IR receptors.

IGF-1 Receptor Activation

IGF-1 DES binds the extracellular alpha subunits of the IGF-1R, triggering autophosphorylation of tyrosine residues in the intracellular beta subunit kinase domain. This recruits adaptor proteins including IRS-1, IRS-2, and Shc, which initiate two principal downstream cascades: the PI3K/Akt/mTOR pathway and the Ras/Raf/MEK/ERK1/2 pathway. PI3K/Akt activation drives protein synthesis, glucose uptake, and anti-apoptotic signaling via mTORC1 and FOXO inhibition, while ERK1/2 signaling promotes mitogenesis and cellular proliferation. Research has shown the binding affinity of IGF-1 DES at IGF-1R is comparable to native IGF-1, with K_d values in the low nanomolar range.

Reduced IGFBP Affinity

The defining mechanistic feature of IGF-1 DES is its dramatically reduced affinity for the IGF binding proteins (IGFBPs), particularly IGFBP-3, which sequesters >90% of circulating native IGF-1. The N-terminal tripeptide Gly-Pro-Glu is a key contact region for IGFBP binding, and its removal reduces IGFBP-3 affinity by approximately 100-fold. Because only free (unbound) IGF-1 can engage the IGF-1R, this property translates into a 5- to 10-fold increase in in vitro potency compared to native IGF-1 in systems containing physiological IGFBP levels. In binding protein–free assays, the two molecules show similar potency, confirming that the enhanced bioactivity is binding protein–dependent.

Tissue Localization and Half-Life

The reduced IGFBP binding gives IGF-1 DES a substantially shorter plasma half-life than IGF-1 LR3 (which retains IGFBP affinity comparable to native IGF-1) — typically reported in the range of 20–30 minutes in preclinical models. This produces a more localized, transient signaling profile at the injection site, which has been investigated in research models of localized hypertrophy and tissue repair.

Downstream Anabolic Effects

Activation of the IGF-1R/PI3K/Akt/mTOR axis stimulates ribosomal S6 kinase (S6K1) and 4E-BP1 phosphorylation, increasing cap-dependent translation and net protein synthesis. In skeletal muscle research models, IGF-1 DES has been associated with satellite cell activation, myoblast proliferation, and myotube hypertrophy. The compound also suppresses muscle protein degradation through Akt-mediated inhibition of FOXO-driven transcription of the atrogenes MuRF1 and atrogin-1.

IGF-1 DES is structurally identical to native human IGF-1 from residue 4 (Thr) onward. The deletion of Gly-Pro-Glu eliminates a critical IGFBP contact surface while preserving the IGF-1R binding interface, the A and B chain–equivalent helical regions, and all three disulfide bridges that maintain tertiary structure. The molecule is stable in lyophilized form when properly stored but is sensitive to repeated freeze-thaw cycles and oxidative degradation due to its methionine residue at position 56.

IGF-1 DES is supplied as a sterile lyophilized powder. It is a 67-amino-acid protein with three intrachain disulfide bonds that are essential for tertiary structure and receptor binding. Improper reconstitution or repeated freeze-thaw cycles can disrupt these disulfides, leading to misfolded aggregates and loss of bioactivity. The reconstitution protocol below preserves structural integrity for downstream research applications.

Recommended Reconstitution Protocol:

1. Allow the lyophilized vial to equilibrate to room temperature (15-30 minutes) before opening. Opening a cold vial allows atmospheric moisture to condense onto the powder.
2. Centrifuge the vial briefly (1,000 x g for 10-15 seconds) to settle any powder adhering to the stopper.
3. Reconstitute with bacteriostatic water or sterile 0.9% sodium chloride. For mildly acidic stabilization, 10 mM acetic acid (pH ~3) is preferred for long-term solution stability.
4. Add the diluent slowly down the inner wall of the vial. Do not inject directly onto the lyophilized cake.
5. Gently swirl or invert the vial. Do not vortex or shake aggressively, as shear forces disrupt disulfide-stabilized folding and promote aggregation.
6. Allow 5-10 minutes for complete dissolution. A clear, colorless solution should result. Discard if visible particulates remain.

Example Concentration: Reconstituting 1 mg of IGF-1 DES in 1 mL of diluent yields a 1 mg/mL (1,000 ug/mL) stock. For research dosing calculations, note that 100 uL of this stock delivers 100 ug.

Compound-Specific Notes:

• Disulfide sensitivity: Avoid reducing agents (DTT, beta-mercaptoethanol) in the working buffer unless intentionally studying denatured protein.
• Adsorption to plasticware: Like other small proteins, IGF-1 DES can adsorb to polypropylene and glass at low concentrations. Add carrier protein (0.1% BSA) for dilutions below 10 ug/mL.
• pH range: Stable between pH 3-7. Avoid alkaline buffers (>pH 8), which accelerate deamidation of asparagine and glutamine residues.
• Light: Not strongly photosensitive, but storage in amber vials is best practice.

All handling should be conducted in a laminar flow hood using sterile technique. IGF-1 DES is intended for in vitro and in vivo research use only.

Proper storage is critical for maintaining the bioactivity of IGF-1 DES. The three intrachain disulfide bonds (Cys6-Cys48, Cys47-Cys52, Cys18-Cys61, using mature IGF-1 numbering shifted for the truncated form) are vulnerable to reduction, scrambling, and oxidation under suboptimal conditions, and the protein is also susceptible to deamidation and aggregation when stored in solution.

Lyophilized Powder Storage:

• Long-term (>1 month): Store at -20 degrees C or colder. -80 degrees C is preferred for storage beyond 12 months. Under these conditions, IGF-1 DES is stable for at least 24 months without measurable loss of receptor binding affinity.
• Short-term (up to 2-4 weeks): May be held at 2-8 degrees C in a desiccated, sealed container.
• Transit: Stable at ambient temperature for 1-2 weeks, as the dry powder is thermodynamically resistant to short-term excursions. Refrigerate immediately upon receipt.

Reconstituted Solution Storage:

• 2-8 degrees C: Reconstituted IGF-1 DES in acetic acid or saline is stable for approximately 14-21 days. Monitor for cloudiness, which indicates aggregation.
• -20 degrees C or -80 degrees C: Aliquot in single-use volumes before freezing. Stable for several months frozen.
• Freeze-thaw: Avoid repeated freeze-thaw cycles. Each cycle introduces interfacial denaturation and disulfide scrambling, with cumulative activity losses of 5-15% per cycle observed in comparable IGF-family proteins.

Stability Risk Factors:

• Disulfide scrambling: Accelerated by alkaline pH, trace metal contamination, and elevated temperature.
• Aggregation: Promoted by agitation, air-liquid interfaces, and concentrations above 5 mg/mL in low-ionic-strength buffers.
• Adsorption losses: Significant for dilute solutions stored in untreated plastic tubes; mitigated by carrier protein or low-binding tubes.

IGF-1 DES should be used within its validated stability window and stored away from direct light, vibration, and frost-free freezer cycles that introduce temperature fluctuation.